BioMarin Reports Q2 2026 Financial Results

What Happened

• BioMarin Pharmaceutical Inc. announced its financial results for the quarter ended June 30, 2026. The company filed a Form 8-K on August 6, 2026 and furnished a press release dated August 6, 2026 as Exhibit 99.1.
• The Form 8-K states the press release is furnished (not “filed”) and therefore is not subject to certain liabilities under the securities laws. The filing was signed by G. Eric Davis, Executive Vice President and Chief Legal Officer.

Key Details

• Filing date: August 6, 2026. Reporting item: 2.02 (Results of Operations and Financial Condition).
• Reporting period: second quarter ended June 30, 2026.
• Press release attached as Exhibit 99.1; cover page Inline XBRL data included as Exhibit 104.
• The company expressly noted the furnished press release is not deemed “filed” for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Why It Matters

• This 8-K notifies investors that BioMarin has released its quarterly earnings and related financial details; those results (revenue, earnings, guidance, or program updates) can affect the stock and investor decisions.
• Retail investors should review the attached press release (Exhibit 99.1) and subsequent SEC filings (e.g., the quarterly Form 10-Q) or company investor materials for the specific revenue, earnings, and guidance figures referenced in this announcement.